Exicure Inc.
XCUR | NASDAQ
$1.23
-$0.03 (-2.38%)
Sep 22, 2026, 2:41 PM ET · Market open
Company Profile
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
Key Executives
| Name | Position |
|---|---|
| Jungsoo Kim | Chief Executive Officer, President & Director |
| Young Seung Ko | Chief Operating Officer |
| Devki Sukhtankar | Head of Preclinical Research & Translational Medicine |
| Gyuyeob Lee | Interim CFO & Secretary |
| Joshua Miller | Chief Accounting Officer |
| Niña Caculitan | Head of Clinical |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 14, 2026 | 10-Q | Quarterly Report |
| Jul 17, 2026 | 4 | Filing |
| Jul 17, 2026 | SC 13D/A | [Amend] Filing |
| Jun 30, 2026 | 8-K | Current Report |
| Jun 01, 2026 | 8-K | Current Report |
| May 29, 2026 | 10-Q | Quarterly Report |
| May 15, 2026 | NT 10-Q | Filing |
| Apr 10, 2026 | 8-K | Current Report |
| Apr 02, 2026 | 8-K | Current Report |
| Mar 27, 2026 | 8-K | Current Report |
Exicure Inc.
| Country | United States |
| IPO Date | May 21, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Jungsoo Kim |
Contact Details
400 Seaport Court Redwood City,
California 94063 United States
Stock Details
| Ticker Symbol | XCUR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001698530 |
| CUSIP Number | 30205M309 |
| ISIN Number | US30205M3097 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove XCUR